NICE rejects breast cancer drug9th July 2010
The National Institute for Health and Clinical Excellence has not approved the use of Avastin to treat breast cancer.
NICE said the drug, known as bevacizumab, was not suitable for use in patients whose cancer had metasised because of "uncertain evidence". "The clinical trial results for bevacizumab were disappointing in that they were unable to prove definitively that the drug could extend the lives of patients with metastatic breast cancer over and above currently available treatments," said NICE Chief Executive Andrew Dillon.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: NICE rejects breast cancer drug
Author: Jess Laurence
Article Id: 15444
Date Added: 9th Jul 2010